Regeneron Pharma (REGN): CMS Draft IRA Guidance May Remove Some Upside Optionality, But Base Case Intact - MS
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $883.00 price target on Regeneron Pharma (NASDAQ: REGN)."Investors are ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
